$MRK · Merck & Co., Inc.

Merck & Co., Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing contains the company’s unaudited consolidated financial statements, including balance sheets, income statements, and cash flow statements, along with management’s discussion and notes to the financial statements. The report provides a standard quarterly update on Merck’s financial position and results of operations for the three and nine months ended September 30, 2026.

The notes to the financial statements include disclosures related to several collaboration, licensing, and acquisition activities. Among these are agreements with AstraZeneca concerning alliance revenue for Lynparza and Koselugo, a license arrangement with Jiangsu Hengrui Pharmaceuticals for HRS-5346, and transactions involving Terns Pharmaceuticals, Cidara Therapeutics, Peloton Therapeutics, SciBrunch Therapeutics, and TARGAN. The filing also references a WuXi vaccines facility asset under construction and a program designated as Sac-TMT.

Because the extracted filing text provided is primarily XBRL tagging and metadata rather than narrative discussion, specific dollar amounts or detailed operational results are not available in this excerpt. The document itself would include the full financial statements and accompanying notes required under SEC rules.